Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 15/20 | 1.00 |
| ▸ | MMP3 | P08254 | 13/20 | 1.00 |
| ▸ | MMP13 | P45452 | 13/20 | 1.00 |
| ▸ | MMP1 | P03956 | 12/20 | 1.00 |
| ▸ | MMP7 | P09237 | 11/20 | 1.00 |
| ▸ | MMP9 | P14780 | 11/20 | 1.00 |
| ▸ | ADAMTS4 | O75173 | 3/20 | 0.77 |
| ▸ | MMP14 | P50281 | 1/20 | 0.74 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7407715 | 1.00 | MMP2 (1.00) | MMP2MMP3MMP13MMP1MMP7 | |
| SCHEMBL4651862 | 0.87 | ADAMTS4 (1.00) | MMP2MMP3MMP13MMP1MMP7 | |
| SCHEMBL1751961 | 0.87 | ADAMTS4 (1.00) | MMP2MMP3MMP13MMP1MMP7 | |
| SCHEMBL7404078 | 0.85 | MMP2 (1.00) | MMP2MMP3MMP13MMP1MMP7 | |
| SCHEMBL4424095 | 0.85 | MMP2 (1.00) | MMP2MMP3MMP13MMP1MMP7 | |
| SCHEMBL4433724 | 0.85 | MMP2 (1.00) | MMP2MMP3MMP13MMP1MMP7 | |
| SCHEMBL14191408 | 0.85 | MMP2 (0.74) | MMP2MMP3MMP13MMP1MMP7 | |
| SCHEMBL19785143 | 0.82 | MMP2 (0.69) | MMP2MMP3MMP13MMP1MMP7 | |
| SCHEMBL7409462 | 0.81 | MMP2 (1.00) | MMP2MMP3MMP13MMP1MMP7 | |
| SCHEMBL7409456 | 0.81 | MMP2 (1.00) | MMP2MMP3MMP13MMP1MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0901466-B1 | BIPHENYLSULFONAMIDE MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2001-10-31 | — | — | EP | claimed |
| CN-1310629-A | Combined administration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions | WARNER LAMBERT CO (US) | 2001-08-29 | — | — | CN | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| EP-0901466-A1 | BIPHENYLSULFONAMIDE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-03-17 | — | — | EP | claimed |
| US-5756545-A | ANTIARTHRITIC AGENTS; OSTEOPOROSIS | WARNER-LAMBERT COMPANY (US) | 1998-05-26 | — | — | US | claimed |
| WO-1997044315-A1 | BIPHENYLSULFONAMIDE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1997-11-27 | — | — | WO | claimed |
| US-20080119513-A1 | Sulfonamide Derivative Selectively Inhibiting Mmp-13 | SHIONOGI & CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-0901466-B1 | BIPHENYLSULFONAMIDE MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2001-10-31 | — | — | EP | disclosed |
| US-5756545-A | ANTIARTHRITIC AGENTS; OSTEOPOROSIS | WARNER-LAMBERT COMPANY (US) | 1998-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119513-A1 | Sulfonamide Derivative Selectively Inhibiting Mmp-13 | MMP13, MMP3, MMP11 | MMP2 10/4885MMP3 2/4885MMP13 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.